LONDON, July 13, 2026 (ITIA Media Release)

Argentinian tennis player Facundo Bagnis has accepted a 12-month suspension under tennis’ anti-doping rules.

36-year-old Bagnis, who reached a career-high world singles ranking of 55 in November 2016, tested positive for hydrochlorothiazide, a diuretic and masking agent on the World Anti-Doping Agency prohibited list, during qualifying for the US Open in August 2025.

While a provisional suspension is not mandatory for this substance, Bagnis elected to enter a voluntary provisional suspension on 18 October 2025 while an investigation took place.

In November 2025, Bagnis informed the ITIA that he had identified a contaminated supplement as the source of the substance found in his sample.

In support of this explanation, Bagnis provided detailed records and documentation, including copies of communication with his doctor, receipts of purchase, and independent expert reports.

On medical grounds, Bagnis’ doctor had prescribed a bespoke supplement and recommended a pharmacy for production, providing assurances of its safety and use by other professional athletes.

In early 2026, the ITIA tested the product at an independent, World Anti-Doping Agency-accredited laboratory. The laboratory both confirmed presence of the substance, and that Bagnis’ explanation was possible.

The ITIA accepted that, in the circumstances, the violation was not intentional. In determining sanction, the mitigating factors demonstrated by Bagnis and precedent from similar cases was considered.

As such, a 12-month suspension was offered to the player, who accepted and waived his right to a hearing before an independent tribunal.

As time served under provisional suspension is credited, Bagnis’ suspension will end on 17 October 2026.

While suspended, Bagnis is not allowed to play in, coach at, or attend any events organised or sanctioned by World Tennis, WTA, ATP, the Grand Slams, or any national association.

To read the decision in full, click here.